Ellingson, J. resolution and neither was manifestation of cytokine-inducible SH2-comprising protein, forkhead package protein 3, GATA3, IL-10, IL-4, IFN-, or T-bet by using real-time PCR in CD25-selected, casein-stimulated mononuclear cells. A calculator to estimate resolution probabilities using baseline milk IgE level, SPT response, and AD severity was devised for use in the medical setting. Conclusions: With this cohort of babies with milk allergy, approximately one half experienced resolved over 66 weeks of follow-up. Baseline milk-specific IgE level, SPT wheal size, and AD severity were all important predictors of the likelihood of resolution. refers to the risk of a beneficial event, namely allergy resolution, and variables are structured so that large relative hazard ideals are associated with increased chance of allergy resolution. Model prediction ability for baseline variable models was summarized with the C index, a concordance measure of expected and observed reactions related to the Kendall rank correlation value.26,27 This measure extends the binary end point assessment of the area under the receiver operating characteristics curve to use with time-to-event data. The C index ranges up to 1 1, and a value of 0.5 indicates no predictive ability. Time-varying medical covariate analyses used the most recent available assessment in the model, and nonproportional risks were examined by fitted linear and spline function relationships with time. For real-time PCR variables, an additional assessment of change from baseline was performed with scores of ?1 when 4 or fewer doublings occurred relative to baseline, 1 when 4 or more doublings Balsalazide relative to baseline occurred, and 0 otherwise. Reported ideals are 2-tailed, when relevant, and SAS 9.2 (SAS, Institute, Cary, NC) and R software were utilized for computations. RESULTS Of the 512 enrolled babies, the cohort with milk allergy consisted of Balsalazide 293 children, of whom 244 were given a analysis of milk allergy at baseline. Among the remaining 49 children, the analysis was classified DES as uncertain at their Balsalazide access visit, but milk allergy was consequently confirmed. Key baseline characteristics are summarized in Table I. A majority (178/293) of subjects were enrolled between 6 and 12 months of age; 192 were male, and 101 were female. AD was present in 261 subjects and was classified as slight in 34, moderate in 146, and severe in 81. Twenty-four babies were given a analysis of milk allergy based on AD criteria, whereas the remainder experienced a history of an acute reaction to milk. One hundred seventeen (39.9%) subjects were also given diagnoses of additional food allergies at their initial evaluation, and another 74 (25.3%) had additional food allergies over the period of observation. TABLE I Baseline characteristics value* .001) in the pace of resolution were noted when comparing those subjects with baseline milk-specific IgE levels of less than 2 kUA/L, 2 to 10 kUA/L, and 10 kUA/L or greater (Fig 2). For example, greater than 70% of those in the lowest milk-specific IgE category experienced resolved milk allergy compared with only 23% of those in the highest category. Significant variations ( .001) in resolution were also predicted by baseline SPT results, while shown in Fig 3, which represents a comparison of subjects with wheal sizes of less than 5 mm, 5 to 10 mm, and greater than 10 mm. In addition, marked variations in resolution ( .001) were detected when comparing those babies presenting with milk allergy who had no or mild AD with those with moderate-to-severe AD (Fig 4). However, baseline milk-specific IgG4 levels were not whatsoever predictive of resolution (observe Fig E1 with this content articles Online Repository at www.jacionline.org), and the milk-specific IgE/IgG4 percentage did not increase further insight to the analyses (data not shown). Open in a.